Takeda, Advinus initiated multi-year drugs discovery collaboration

Thursday, October 4, 2012 02:19 PM

Takeda Pharmaceutical, a Japanese research-based pharmaceutical company, and Advinus Therapeutics, a privately held research-based pharmaceutical company based in India, have entered into an agreement to initiate a three-year discovery collaboration focused on novel targets for major therapeutic areas, including inflammation, CNS and metabolic diseases.

Takeda will receive worldwide commercial rights to drug candidates emerging from this alliance. Advinus will receive guaranteed research funding of $36 million over the term of the collaboration, $9 million in milestones leading to candidate selection and is eligible to receive future clinical and regulatory milestone payments of up to $45 million per product, plus royalties on product sales worldwide. Advinus is also responsible for leading the programs to create optimal IND-ready compounds for pre-defined targets.

"Advinus’ team is delighted that its biggest ever collaboration has been made possible by Takeda's visionary leadership, and their confidence in the founding principles that aim to create these new R&D opportunities," said Rashmi Barbhaiya, CEO of Advinus.

"Collaboration with Advinus is one of our initiatives to enhance our research productivity," said Paul Chapman, general manager, pharmaceutical research, Takeda. "We are very excited to partner with Advinus as they have innovative approaches to efficiently generate INDs that will further strengthen Takeda's drug discovery capabilities, while also enhancing our pipeline."

Share:          
CWWeekly

June 29

FDA and PatientsLikeMe collaborate to test social media adverse event reporting

Boston-area teaching hospitals launch web portal to attract life science companies

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs